[This review was originally posted at the Nieman Journalism Lab Synthroid Dosage, on Oct. 21, 2011.]

Growing tension at News Corp.: We'll be hearing the news from News Corp.'s annual shareholder meeting later today, and media observers are certainly watching the meeting closely, especially after reports late last week that numerous groups representing about a quarter of the company's investors are planning on voting against many of News Corp.'s board members.

The list of problems at News Corp. has continued to lengthen over the past three months, What is Synthroid, and an analyst interviewed by NPR's David Folkenflik asserted that in an ordinary company, the board would have fired the CEO by now. But Rupert Murdoch, of course, is no ordinary CEO. But even in the close-knit top leadership of News Corp., this scandal is leading to significant tension between Murdoch and his son, James, who was until recently the company's heir apparent, Synthroid Dosage. A New York Times report this week gave details of the power struggles in the Murdoch family, and Reuters' Jack Shafer pointed out that public family squabbles aren't new for the Murdochs.

Both media analyst Alan Mutter and the Guardian's Dan Gillmor were doubtful, after Synthroid, however, that the complaints of investors would make any sort of difference in the way News Corp. is run, especially since Murdoch has a 40% share in the company. "As long as Rupert Murdoch is in control, there are only two factors that will lead to change: a genuine threat to his family's money and power, Purchase Synthroid online, " Gillmor said. Synthroid Dosage, Without those threats, he argued, shareholders aren't going to see a change in direction.

And amid all of this, News Corp.'s various scandals continue to play out publicly. On the phone-hacking front, an attorney who did work for News Corp. told Parliament that he knew the company had misled Parliament about the extent of the hacking but did nothing about it.

And on the Wall Street Journal's circulation inflation, News Corp. reportedly knew about the issue almost a year before its executive resigned over it, Synthroid coupon, and Poynter's Steve Myers found that WSJ Asia also relies heavily on deeply discounted issues. But the Journal isn't the only one that relies on those discounted circulation ploys: The Guardian's Roy Greenslade noted that three major U.K, Synthroid Dosage. papers do, and Poynter's Rick Edmonds said some U.S. papers do as well. Media analyst Frederic Filloux warned of the effects of this kind of culture of cheating: "such tricks push prices further down because media buyers increasingly distrust the system. Today, Synthroid from canada, they apply the rule 'you cheat, we cut prices'. And the downward spiral continues."

—

Getting identity right online Synthroid Dosage, : Google+ announced a big change in its policies this week, giving word that it will soon amend its real-names-only rule to allow pseudonyms. That policy has been the subject of much debate over the past couple of months, and the coming change prompted Electronic Freedom Foundation to declare victory. Programmer Jamie Zawinski called that statement "shamefully credulous" and wondered why it's going to take months to implement. He predicted that Google+ will still require real names, but will allow nicknames and pseudonyms in addition.

Before its change, Synthroid mg, Google+ had drawn some more criticism for its identity policy. Christopher "moot" Poole has been one of the more prominent advocates for anonymity online — it's central to 4chan, the image-based message board he founded — and he articulated his position again this week in a short tech-conference speech, Synthroid Dosage. (Good summaries by VentureBeat and ReadWriteWeb.) This time, he targeted the identity policies of Facebook and Google+, saying they try to force-fit people into a single identity, when they're really much more complex than that.

"Google and Facebook would have you believe that you’re a mirror, Get Synthroid, but we’re actually more like diamonds," Poole said. "Look from a different angle, and you see something completely different." He argued that Google+ missed a big opportunity to innovate by allowing users to manipulate who they share with, rather than who they share as. Twitter has a better handle on identity, he said, as an interest-based community, japan, craiglist, ebay, overseas, paypal, rather than an identity-based one.

Wired's Tim Carmody praised Poole's philosophy of identity Synthroid Dosage, , arguing that it's practical without surrendering to Facebook's one-identity-for-all-time mantra. And GigaOM's Mathew Ingram also praised Twitter's approach, arguing that its commitment to free speech is far more important than whether participants are using their real names.

—

Making nonprofit news sustainable: The Knight Foundation released a comprehensive report on what makes local nonprofit news organizations work, featuring profiles of eight orgs, including many of the big names in that corner of the news world — Bay Citizen, Generic Synthroid, MinnPost, Voice of San Diego, Texas Tribune, and so on.

The study highlighted three keys to sustainability for local nonprofit news orgs: First, a workable business development strategy, which means that even if they start with foundation support, they need to treat it as something that will diminish over time, Synthroid dangers, rather than an ongoing revenue stream. Second, they need innovative approaches to building engagement both online and offline. And third, they need the skills to go deep into data journalism and interactive features, which "require technological capacity that sits outside the experience of many journalists."

Poynter's Rick Edmonds dug deeper into the study, noting a couple of other interesting tidbits: Though the sites are working hard to diversify their funding, more than half of it is still coming from foundations, and another third from donations, Synthroid Dosage. He also said these news sites need to have deep community roots and be able to adapt to specific local information needs, rather than just having a general "replace what's gone" goal.

—

Apple's Newsstand starts strong: It's only been around a little more than a week, but according to a couple of app sellers, Synthroid description, the early indicators on Apple's new Newsstand have been quite positive. Exact Editions and Future, two companies that produce and sell apps for publishers, said that sales have more than doubled across the board since Newsstand's launch, according to paidContent. The Daily was the biggest winner, coming out No. 1 on Newsstand's first bestseller list, taking Synthroid. Synthroid Dosage, While noting that it's very early, Jessica Roy of 10,000 Wordscalled the news "incredibly encouraging for digital publishers."

At the Knight Digital Media Center, Amy Gahran wondered whether Newsstand's popularity and ease of use will eventually spell the end of standalone iPhone and iPad news apps. That may not be a bad thing, she said: "Standalone news apps may look cool, but cumulatively they’re also a hassle for users who mainly just want access to content, not special interactive features." Meanwhile, another news org, the Economist, Synthroid used for, has had to give in to Apple's requirements that app payments go through its App Store, rather than through the web.

—

Reading roundup: Here's what else went on in the world of news and tech in the past week:

— Google announced it would shut down a few services: Code Search, which lets people look up open-source code, and two social networks, Jaiku and Google Buzz. ReadWriteWeb's Marshall Kirkpatrick reflected on Buzz's privacy problems, and j-prof Josh Braun said Buzz reminds us that a social network site doesn't have to be huge to be priceless, buy Synthroid no prescription. Mathew Ingram of GigaOM wondered if Google has really learned all that much from Buzz and Jaiku.

— The New York Times' David Streitfeld wrote on Amazon's burgeoning business as a book publisher, both online and in print, Synthroid Dosage. Mathew Ingram told publishers to wake up and realize that they're a middleman that people are figuring out how to eliminate.

— The Guardian gave an update after a week its open-newslist experiment, reporting that it's drawn quite a bit of interest from readers and that it's been expanded to include longer-range plans. The Journal Register Co.'s Steve Buttry noted that some of his company's papers are doing this, too. Online buying Synthroid, — After its initial five-year run ended, the Knight Foundation announced its Knight News Challenge will continue in 2012, being run three times a year.

— The real-time web got a real breaking-news test yesterday when the news of former Libyan leader Muammer Gaddafi had died broke with numerous conflicting reports. Poynter's Julie Moos looked at how major news sites handled the uncertainty.

— It's something that's harped on for at least a decade, but Poynter's Mallary Jean Tenore showed that news orgs still have a ways to go in providing accessible contact information for their journalists.

Similar posts: Flagyl Over The Counter. Bactrim Dosage. Zoloft Cost. Cipro no prescription. Taking Retin A. Order Flagyl from mexican pharmacy.
Trackbacks from: Synthroid Dosage. Synthroid Dosage. Synthroid Dosage. Synthroid dosage. Buy generic Synthroid. Generic Synthroid.

[This review was originally posted at the Nieman Journalism Lab Diflucan Dosage, on June 10, 2011.]

Apple’s mobile Newsstand is a reality: When Steve Jobs makes an announcement, it’s a pretty good bet that whatever he introduces will be what the media-tech world is talking about for the next week (or month, or year). On Monday, Jobs had plenty to introduce — led by a new Mac operating system (Lion), mobile operating system (iOS 5), and a new cloud service to replace MobileMe (iCloud). Those developments have implications for several different aspects of news and media, Diflucan mg, and I’ll try to run down as many of them as I can.

The most direct impact will likely come from Newsstand, an app Jobs unveiled that will be similar to iBooks, providing a single place for all of a user’s magazine and newspaper app subscriptions.

TechCrunch called it evidence that Apple is emphasizing that the iPad is for reading, while GigaOM’s Mathew Ingram and the Guardian’s Jemima Kiss saw a trade-off for publishers: A simpler subscription interface (which likely means more renewals), but even more control for Apple. For consumers, as the Lab’s Andrew Phelps and Megan Garber noted, purchase Diflucan online no prescription, it’s the closest digital publishing has come to the traditional distribution model of regular home delivery.

Apple’s new operating systems will include a raft of upgrades, many of which overlap with existing third-party apps. The New York Times’ Bits blog has a good breakdown of what apps might be threatened, led by the reading-list creator Instapaper, as Apple will begin offering a similar basic function as part of Safari. Instapaper founder Marco Arment was understandably perturbed by the news, but later reasoned that the upgrade could make saving things to read later a built-in part of the workflow of millions of Apple users — and that if even a small percentage of them want a deluxe version of that service, Instapaper will still be in fine shape. The point was echoed by The Next Web’s Matthew Panzarino and by Andrew and Megan here at the Lab.

—

Apple eases up — kind of: Apple made another significant change this week, too, this one without an announcement, Diflucan Dosage. Order Diflucan online c.o.d, As MacRumors discovered yesterday, Apple quietly adjusted its policy on in-app subscriptions, allowing publishers to sell in-app subscriptions for whatever price they want (previously, they had to be at least as cheap as app subscriptions outside Apple’s store) and lifting the requirement that subscriptions must be offered within the app itself.

All Things Digital’s Peter Kafka has a good explanation of the change, noting that Apple may be allowing companies to circumvent its App Store, but it’s not going to let it be easy. (You still can’t, for example, Diflucan without a prescription, include in your app a “Buy” button pointing users to subscribe via your website.) Still, the lifting of the price restriction could be an encouragement for publishers because, as paidContent’s Staci Kramer pointed out, now they can raise prices to absorb Apple’s 30% revenue cut.

But that doesn’t mean publishers will end up taking advantage of their newfound freedoms. The Lab’s Joshua Benton argued that most publishers won’t, Rx free Diflucan, because customers will resist varied app prices and because Apple’s app purchasing system offers some significant value to publishers that might be worth its 30% cut. And media analyst Ken Doctor reminded us that Apple still holds just about all the cards in this hand.

Poynter’s Jeff Sonderman made an interesting observation: Apple seems to be using the adjusted guidelines to funnel app subscriptions into its new Newsstand. Newsstand’s likely prominence still leaves plenty of open questions for publishers (including the ones outlined earlier), Sonderman said.

—

The Financial Times hedges its bets on Apple: One publisher stated quite emphatically this week that it’s not going to play Apple’s game: The Financial Times unveiled a mobile web app intended as an alternative to Apple’s App Store-based apps.

By using an HTML5-based app, the FT can design a single app for any major mobile device and get around Apple’s 30 percent cut of app subscriptions, but its apps may get pulled from the App Store. Diflucan Dosage, (The next day, the FT responded to Apple’s new guidelines with what sounded like indignation, sounding as though they’ll charge forward.)

An FT exec told the Guardian that the app was something of a line in the sand, resulting from what he called a “Mexican standoff” with Apple. The move was heralded as a critical one in the tug-of-war between Apple and publishers: All Things Digital called it the first attempt by a major news org to create an HTML5 app that feels just like an App Store app, Diflucan street price, and paidContent said the move was “significant and brave,” especially since its Apple-native apps have been so successful.

Bobbie Johnson of GigaOM wondered if this would be the catalyst news orgs need to start standing up to Apple, and Ken Doctor said the FT’s main value would be in providing a counterweight to the Apple-centric market, as well as experiments for other news orgs to learn from. Benedict Evans, Diflucan cost, meanwhile, said the FT may have a dedicated readership to pull this off where other news orgs can’t.

There were a few voices pushing back against the “FT goes to war with Apple” narrative: Noting that the FT says it has no plans of leaving the App Store, the Lab’s Andrew Phelps argued that “FT’s web app could be less about shunning Apple and more about working with it: keeping one foot inside Apple’s garden, and the other outside.” Doctor talked about the FT’s strategy as a blueprint for news orgs to use Apple as Apple uses them.

And both Phelps and Poynter’s Jeff Sonderman noted that the FT’s not the first news org to try this approach, as NPR and others have dabbled in HTML5 apps before. U.K.-based journalist Kevin Anderson reviewed the app and concluded that HTML5 will soon be “the standard that enables the next wave of cross-platform innovation."

—

The metered model gets a closer look: Ever since early last year, when the New York Times announced its plans to charge for its website through a metered model, Diflucan canada, mexico, india, that form of online paid content has gotten far more attention than any other. This week, French media consultant Frederic Filloux offered a useful explainer for the model, detailing how it works, what goes into publishers’ decisions about how to implement them, Online buying Diflucan, and where they fit among other paid-content models. One of its major appeals, he argued, is that advertisers see visitors who have paid up as much more valuable, paying as much as a 30 percent premium to reach them.

Filloux presented the metered model as a way of combating the overreliance on one-time, fly-by web visitors by news sites, Diflucan Dosage. British journalist Kevin Anderson echoed those concerns, calling for news orgs to “move to more honest and realistic metrics” and separate out “bounce” visitors, or those who stay on the site for only a few seconds, from their traffic figures. Meanwhile, Filloux’s metered-model math didn’t sway GigaOM’s Mathew Ingram, Diflucan results, who said he still opposes it as a fundamentally backwards-facing strategy.

Another piece of paid-content news worth noting briefly: Outgoing Fox News personality Glenn Beck’s new Internet broadcast-style network will employ a monthly subscription fee. You can check out the commentary on his venture at Mediagazer.

—

A local reporting crisis: The U.S. Federal Communications Commission added fuel to the long-simmering discussion over the future of accountability reporting in a digital media environment this week, releasing a study finding that the U.S. faces a critical shortage of local reporting, leaving local governmental bodies with an alarming power to influence the news agenda without being checked.

As the Lab’s Megan Garber noted, Diflucan from mexico, its bleak picture of local reporting and many of its proposed solutions were nothing new, except for its recommendation that the government make efforts to funnel advertising into local media, rather than national. Gawker’s Hamilton Nolan said now is a ripe time Diflucan Dosage, for a local news reporting resurgence and urged young reporters to stay away from media centers like New York and flock to small towns instead, and the Atlantic Wire’s Adam Clark Estes looked at how to make that resurgence a reality.

—

A crackup at AOL?: Henry Blodget of Business Insider calculated a tidbit about the post-merger AOL which, if true, is pretty startling: It now has a larger editorial staff than The New York Times. But just because the new, content-oriented AOL is big doesn’t mean it’s stable. A few days earlier, Business Insider published an anonymous note by an AOL staffer painting a picture of a corporate culture marked by paranoia, buy Diflucan no prescription, dissension, and incompetence.

In a more thoroughly reported story, Forbes’ Jeff Bercovici found a similarly grim situation at AOL, revealing a misunderstanding on AOL’s part about how the Huffington Post’s business model works and a dysfunctional sales department, among other problems. Business Insider came back later in the week with a conversation with an anonymous Patch editor who described low morale, Diflucan dose, sagging ad sales, poor leadership and a clueless business model.

Gawker’s Ryan Tate combed through the two pieces for a good, quick rundown of the charges levied against Arianna Huffington, and the Atlantic Wire’s John Hudson also put together a good summary of what’s wrong.

—

Reading roundup: Whew. Here’s what else folks were talking about this week:

— We found out a bit more about the New York Times’ new executive editor, Jill Abramson. Here are profiles and interviews from the New York Observer, get Diflucan, Los Angeles Times, Guardian, Adweek, Low dose Diflucan, and Women’s Wear Daily. Don’t have time for all that, Diflucan Dosage. The Atlantic Wire has a good roundup.

— A new site worth keeping an eye on, especially for sports fans: Grantland, a project of ESPN columnist Bill Simmons, launched this week. Simmons has called it a Miramax to ESPN’s Disney, and former ESPNer Dan Shanoff is optimistic about its chances. Simmons said he’s not into chasing pageviews, and here at the Lab, Tim Carmody looked at Simmons’ effort to find success at the intersection of sports and pop culture.

— Also at the Lab, Justin Ellis took a look at Hacks/Hackers and the future of the niche Q&A site.

— The Knight Digital Media Center’s Amy Gahran suggested the “Lego approach” to storytelling as a way to add context and integration to journalism.

— Finally, one great practical piece and another one to think on. At the Columbia Journalism Review, Craig Silverman got some fantastic tips from various social media experts about how to verify information on social media, and NYU j-prof Jay Rosen took stock of where “pro-am journalism” is and where it’s headed.

Similar posts: Buy Armour No Prescription. Purchase Lipitor. Flagyl Mg. Bactrim photos. Effects of Retin A. Where can i buy Synthroid online.
Trackbacks from: Diflucan Dosage. Diflucan Dosage. Diflucan Dosage. Order Diflucan online overnight delivery no prescription. Diflucan samples. Australia, uk, us, usa.

[This review was originally posted at the Nieman Journalism Lab Tramadol Over The Counter, on Jan. 7, 2011.]

A net neutrality compromise: The Review might have taken two weeks off for the holidays, but the rest of the future-of-news world kept on humming. Consider this more your "Holidays in Review" than your "Week in Review." Let's get to it.

The biggest news development of the past few weeks came just before Christmas, when the FCC passed a set of Internet regulations that were widely characterized as a compromise between net neutrality advocates and big Internet service providers. Tramadol pharmacy, In essence, the rules will keep ISPs from blocking or slowing services on the traditional wired Internet, but leave the future of wireless regulation more unclear. (Here's a copy of the order and a helpful explainer from GigaOM.)

In the political realm, the order drew predictable responses from both sides of the aisle: Conservatives (including at least one Republican FCC commissioner) were skeptical of a move toward net neutrality, while liberals (like Democratic Sen. Al Franken) fervently argued for it, Tramadol Over The Counter. In the media-tech world, it was greeted — as compromises usually are — with near-universal disdain. The Economist ran down the list of concerns for net neutrality proponents, led by the worry that the FCC "has handed the wireless carriers a free pass." This was especially troubling to j-prof Dan Kennedy, who argued that wireless networks will be far more important to the Internet's future than wired ones, Tramadol samples.

Salon's Dan Gillmor said the FCC paid lip service to net neutrality, paving the way for a future more like cable TV than the open web we have now. Newsweek's Dan Lyons compressed his problems with the order into one statement: "There will soon be a fast Internet for the rich and a slow Internet for the poor."

From the other side, Slate media critic Jack Shafer, a libertarian, questioned whether the FCC had the power to regulate the Internet at all, Order Tramadol no prescription, and imagined what the early Internet would have been like if the FCC had regulated it then. The Los Angeles Times' James Rainey told both sides Tramadol Over The Counter, to calm down, and at the Knight Digital Media Center, Amy Gahran used the story as an object lesson for news organizations in getting and linking to the source documents in question.

—

WikiLeaks and the media's awkward dance: The long tail of this fall's WikiLeaks story continues to run on, meandering into several different areas over the holidays. There are, of course, ongoing efforts to silence WikiLeaks, both corporate (Apple pulled the WikiLeaks app from its store) and governmental (a bill to punish circulation of similar classified information was introduced, and criticized by law prof Geoffrey Stone), online buying Tramadol.

In addition, Vanity Fair published a long piece examining the relationship between WikiLeaks' Julian Assange and The Guardian, the first newspaper to partner with him. Based on the story, Slate's Jack Shafer marveled at Assange's shrewdness and gamesmanship ("unequaled in the history of journalism"), Reuters' Felix Salmon questioned Assange's mental health, Buy cheap Tramadol, and The Atlantic's Nicholas Jackson wondered why The Guardian still seems to be playing by Assange's rules.

We also saw the blowup of Salon columnist Glenn Greenwald's feud with Wired over some chat logs between alleged WikiLeaks leaker Bradley Manning and the man who turned him in, Tramadol Over The Counter. It's a complicated fight I'm not going to delve into here, but if you'd like to know more, here are two good blow-by-blows, one more partial to Wired, and another more sympathetic to Greenwald.

Greenwald has also continued to be one of the people leading the inquiries into the traditional media's lack of support for WikiLeaks. Alternet rebutted several media misconceptions about WikiLeaks, rx free Tramadol, and Newsweek attempted to explain why the American press is so lukewarm on WikiLeaks — they aren't into advocacy, and they don't like Assange's purpose or methods. One of the central questions to that media cold-shoulder might be whether Assange is considered a journalist, something GigaOM's Mathew Ingram tried to tackle. Tramadol Over The Counter, Other, more open critiques of WikiLeaks continue to trickle out, including ones from author Jaron Lanier and Floyd Abrams, a lawyer who argued for The New York Times in the Pentagon Papers case. Abrams' argument prompted rebuttals from Jack Shafer and NYU prof Clay Shirky. Shirky in particular offered a nuanced comparison of the Pentagon Papers-era Times and the globally oriented WikiLeaks, concluding that "the old rules will not produce the old outcomes." If you're still hungry for WikiLeaks analysis, Tramadol trusted pharmacy reviews, John Bracken's rounded up the best of the year here.

—

Looking back, and looking forward: We rang in the new year last week, and that, of course, always means two things in the media world: year-end retrospectives, and previews of the year to come. The Lab wrapped up its own year in review/preview before Christmas with a review of Martin Langeveld's predictions for 2010. PBS' MediaShift also put together a good set of year-end reviews, order Tramadol online c.o.d, including ones on self-publishing, the rapidly shifting magazine industry, a top-ten list of media stories (led by WikiLeaks, Facebook, and the iPad). You can also get a pretty good snapshot of the media year that was by taking a look at AOL's list of the top tech writing of 2010.

Poynter's Rick Edmonds examined the year in newspaper stock prices (not great, but could've been worse), while media consultant Alan Mutter explained that investors tended to stay away from debt-laden newspaper companies in particular, Tramadol Over The Counter. Get Tramadol, As for the year to come, the Lab's readers weighed in — you like ProPublica, The Huffington Post, and Clay Shirky, and you're split on paywalls — and several others chimed in with their predictions, too. Among the more interesting prognostications: New York Times media critic David Carr sees tablets accelerating our ongoing media convergence, The Next Web forecasts a lot of blogs making the Gawker-esque beyond the blog format, online buy Tramadol without a prescription, Mashable's Vadim Lavrusik predicts the death of the foreign correspondent, TBD's Steve Buttry sees many journalism trade organizations merging, and the Lab's Martin Langeveld thinks we'll see John Paton's innovative measures at the Journal Register Co. slowly begin to be emulated elsewhere in the newspaper industry.

Two other folks went outside the predictions mold for their 2011 previews: media analyst Ken Doctor looked at 11 pieces of conventional wisdom the media industry will test this year, and the University of Colorado's Steve Outing outlined his wishes for the new year. Tramadol Over The Counter, Specifically, he wants to see News Corp. My Tramadol experience, and The New York Times' paid-content plans fail, and to see news execs try a value-added membership model instead. "This will require that news publishers actually work their butts off to sell, rather than sit back and expect people to fork over money "just because" everyone should support journalism," he wrote.

—

Rethinking publishing for the tablet: One theme for the new year in media that's already emerged is the impending dominance of the tablet. As The New York Times' Joshua Brustein wrote, that was supposed to be the theme last year, too, Tramadol recreational, but only the iPad was the only device able to get off the ground in any meaningful way. Several of Apple's competitors are gearing up to make their push this year instead; The Times' Nick Bilton predicted that companies that try to one-up Apple with bells and whistles will fail, though Google may come up with a legitimate iPad rival.

Google has begun work toward that end, looking for support from publishers to develop a newsstand to compete with Apple's app store, Tramadol Over The Counter. And Amazon's Kindle is doing fine despite the iPad's popularity, TechCrunch argued. Meanwhile, Tramadol from mexico, Women's Wear Daily reported that magazine app sales on the iPad are down from earlier in the year, though Mashable's Lauren Indvik argued that the numbers aren't as bad as they seem.

The magazine numbers prompted quite a bit of analysis of what's gone wrong with magazine apps. British entrepreneur Andrew Walkingshaw ripped news organizations for a lack of innovation in their tablet editions — "tablets are always-on, tactile, completely reconfigurable, great-looking, permanently jacked into the Internet plumbing, Tramadol results, and you’re using them to make skeumorphic newspaper clones?" — and French media consultant Frederic Filloux made similar points, urging publishers to come up with new design concepts and develop a coherent pricing structure (something Econsultancy's Patricio Robles had a problem with, too). Tramadol Over The Counter, There were plenty of other suggestions for tablet publications, too: GigaOM's Mathew Ingram said they should focus on filtering the web, MG Siegler of TechCrunch asked for an easy-to-use newsstand rather than a system of standalone apps, and Alan Mutter suggested magazines lower the prices and cut down on the technical glitches.

Three others focused specifically on the tablet publishing business model: At the Lab, Ken Doctor gave us three big numbers to watch in determining where this is headed, entrepreneur Bradford Cross proposed a more ad-based model revolving around connections to the open web, After Tramadol, and venture capitalist Fred Wilson predicted that the mobile economy will soon begin looking more like the web economy.

—

Reading roundup: A few items worth taking a look at over the weekend:

— The flare-up du jour in the tech world is over RSS, and specifically, whether or not it is indeed still alive. Web designer Kroc Camen suggested it might be dying, TechCrunch's MG Siegler fingered Twitter and Facebook as the cause, Dave Winer (who helped develop RSS) took umbrage, and GigaOM's Mathew Ingram and The Guardian's Martin Belam defended RSS' relevance.

— Add the Dallas Morning News to the list of paywalled (or soon-to-be-paywalled) papers to watch: It announced it will launch a paid-content plan Feb. 15, Tramadol Over The Counter. The Lab's Justin Ellis shed light on Morning News' thinking behind the plan. PaidContent's Staci Kramer alsobroke down a Pew report on paying for online content.

— For the many writers are considering how to balance social media and longer-form writing, two thoughtful pieces to take a look at: Wired's Clive Thompson on the way tweets and texts can work in concert in-depth analysis, and Anil Dash on the importance of blogging good ideas.

— Finally, NPR's Matt Thompson put together 10 fantastic lessons for the future of media, all coming from women who putting them into action. It's an encouraging, inspiring set of insights.

Similar posts: Purchase Cephalexin. Order Glucophage. Lipitor Price. Low dose Zoloft. Lipitor duration. Zoloft pictures.
Trackbacks from: Tramadol Over The Counter. Tramadol Over The Counter. Tramadol Over The Counter. Tramadol natural. Tramadol pharmacy. Tramadol no rx.